In the first-in-human clinical trial, irradiated CAR-NK-92 cells were detectable 3 days after their infusion in two acute myeloid leukemia (AML) patients (NCT02944162, phase I trial of CD33-CAR NK-92 cells in three patients with RR-AML) [55]. The gene discussed is CD33; the disease is acute myeloid leukemia.